Update on US launch
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that, in its HY 2024 results announcement released this morning, Haleon has confirmed that it expects Eroxon to be available in the US before the end of this year.
The Company also confirms that trading remains in line with current market expectations for FY2024. Current market expectations do not include any contribution from the US launch in FY2024. As previously announced, the Company plans to give updated guidance on trading at the time of its Interim results in September.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.